A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product

A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product

Cilostazol is a selective inhibitor of type 3 phosphodiesterase. 5-(3-Chloropropyl)-1-cyclohexyl-1H-tetrazole, used as an intermediate in the synthesis of cilostazol, has a primary alkyl chloride group, a well-known alerting function for genotoxic activity. Upon request from a regulatory agency, a l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientia pharmaceutica 2015-01, Vol.83 (2), p.269-278
Hauptverfasser: Bray, Luigi, Monzani, Luca, Brunoldi, Enrico, Allegrini, Pietro
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 278
container_issue 2
container_start_page 269
container_title Scientia pharmaceutica
container_volume 83
creator Bray, Luigi
Monzani, Luca
Brunoldi, Enrico
Allegrini, Pietro
description Cilostazol is a selective inhibitor of type 3 phosphodiesterase. 5-(3-Chloropropyl)-1-cyclohexyl-1H-tetrazole, used as an intermediate in the synthesis of cilostazol, has a primary alkyl chloride group, a well-known alerting function for genotoxic activity. Upon request from a regulatory agency, a limit test in accordance with ICH Q2(R1) added with the accuracy of a recovery test of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole in cilostazol was developed and validated. The application of the method highlighted the need to optimize the purification process to ensure levels of this potential genotoxic impurity in the final active pharmaceutical ingredient below the established limit. Also, the analytical method was suitable to determine the amount of the impurity in samples of the commercially available drug product, which showed the levels to be above the established threshold of toxicological concern (TTC).
doi_str_mv 10.3797/scipharm.1502-05
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4727775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3716164231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-bbb191c0a05e6153338671fbe3609c7de5f6ba5bf1868d83b1fe57104ce30fdc3</originalsourceid><addsrcrecordid>eNpdkkFv1DAQhS0EotvCnRMaiQuXtHac2N4L0irQdqWtWEThajmO03XlxFvbqVj-EH8TL9tWwMm25puneeOH0BuCTymf87Oo7XajwnBKalwWuH6GZmVJRL7R8jmaYUxZITieH6HjGG8xZqQi_CU6Kpmgc1HiGfq1gO_K2U4l08HletWcXX2FlR1sgmsTE1yZtPEd9D6AgrVPZkxWObgwo0_-h9WwHLZTsGkHdoTGOh-T-ukdqLEDmyJ8mVTu6K1WyfpxD6WNgcV6eSAOz8YPgwk6C7sdLO6Vdap1Bj6G6QbWwXeTTq_Qi165aF4_nCfo2_mn6-ayWH2-WDaLVaEp56lo25bMicYK14aRmlIqGCd9ayjDc807U_esVXXbE8FEJ2hLelNzgittKO47TU_Qh4PudmoH0-nsNygnt8EOKuykV1b-WxntRt74e1nxknNeZ4H3DwLB3015hXKwURvn1Gj8FCXhLG-_whXJ6Lv_0Fs_hTHbk4QJkRXpHwofKB18jMH0T8MQLPcpkI8pkPsUSLyf4e3fJp4aHr-d_gZegrIS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1688472341</pqid></control><display><type>article</type><title>A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Bray, Luigi ; Monzani, Luca ; Brunoldi, Enrico ; Allegrini, Pietro</creator><creatorcontrib>Bray, Luigi ; Monzani, Luca ; Brunoldi, Enrico ; Allegrini, Pietro</creatorcontrib><description>Cilostazol is a selective inhibitor of type 3 phosphodiesterase. 5-(3-Chloropropyl)-1-cyclohexyl-1H-tetrazole, used as an intermediate in the synthesis of cilostazol, has a primary alkyl chloride group, a well-known alerting function for genotoxic activity. Upon request from a regulatory agency, a limit test in accordance with ICH Q2(R1) added with the accuracy of a recovery test of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole in cilostazol was developed and validated. The application of the method highlighted the need to optimize the purification process to ensure levels of this potential genotoxic impurity in the final active pharmaceutical ingredient below the established limit. Also, the analytical method was suitable to determine the amount of the impurity in samples of the commercially available drug product, which showed the levels to be above the established threshold of toxicological concern (TTC).</description><identifier>ISSN: 0036-8709</identifier><identifier>EISSN: 2218-0532</identifier><identifier>DOI: 10.3797/scipharm.1502-05</identifier><identifier>PMID: 26839820</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><ispartof>Scientia pharmaceutica, 2015-01, Vol.83 (2), p.269-278</ispartof><rights>Copyright Österreichischer Apotheker-Verlagsgesellschaft m.b.H (Austrian Pharmacists' Publishing House) 2015</rights><rights>Copyright: © Bray 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727775/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727775/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26839820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bray, Luigi</creatorcontrib><creatorcontrib>Monzani, Luca</creatorcontrib><creatorcontrib>Brunoldi, Enrico</creatorcontrib><creatorcontrib>Allegrini, Pietro</creatorcontrib><title>A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product</title><title>Scientia pharmaceutica</title><addtitle>Sci Pharm</addtitle><description>Cilostazol is a selective inhibitor of type 3 phosphodiesterase. 5-(3-Chloropropyl)-1-cyclohexyl-1H-tetrazole, used as an intermediate in the synthesis of cilostazol, has a primary alkyl chloride group, a well-known alerting function for genotoxic activity. Upon request from a regulatory agency, a limit test in accordance with ICH Q2(R1) added with the accuracy of a recovery test of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole in cilostazol was developed and validated. The application of the method highlighted the need to optimize the purification process to ensure levels of this potential genotoxic impurity in the final active pharmaceutical ingredient below the established limit. Also, the analytical method was suitable to determine the amount of the impurity in samples of the commercially available drug product, which showed the levels to be above the established threshold of toxicological concern (TTC).</description><issn>0036-8709</issn><issn>2218-0532</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkkFv1DAQhS0EotvCnRMaiQuXtHac2N4L0irQdqWtWEThajmO03XlxFvbqVj-EH8TL9tWwMm25puneeOH0BuCTymf87Oo7XajwnBKalwWuH6GZmVJRL7R8jmaYUxZITieH6HjGG8xZqQi_CU6Kpmgc1HiGfq1gO_K2U4l08HletWcXX2FlR1sgmsTE1yZtPEd9D6AgrVPZkxWObgwo0_-h9WwHLZTsGkHdoTGOh-T-ukdqLEDmyJ8mVTu6K1WyfpxD6WNgcV6eSAOz8YPgwk6C7sdLO6Vdap1Bj6G6QbWwXeTTq_Qi165aF4_nCfo2_mn6-ayWH2-WDaLVaEp56lo25bMicYK14aRmlIqGCd9ayjDc807U_esVXXbE8FEJ2hLelNzgittKO47TU_Qh4PudmoH0-nsNygnt8EOKuykV1b-WxntRt74e1nxknNeZ4H3DwLB3015hXKwURvn1Gj8FCXhLG-_whXJ6Lv_0Fs_hTHbk4QJkRXpHwofKB18jMH0T8MQLPcpkI8pkPsUSLyf4e3fJp4aHr-d_gZegrIS</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Bray, Luigi</creator><creator>Monzani, Luca</creator><creator>Brunoldi, Enrico</creator><creator>Allegrini, Pietro</creator><general>MDPI AG</general><general>The Austrian Journal of Pharmaceutical Sciences</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BFMQW</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product</title><author>Bray, Luigi ; Monzani, Luca ; Brunoldi, Enrico ; Allegrini, Pietro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-bbb191c0a05e6153338671fbe3609c7de5f6ba5bf1868d83b1fe57104ce30fdc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bray, Luigi</creatorcontrib><creatorcontrib>Monzani, Luca</creatorcontrib><creatorcontrib>Brunoldi, Enrico</creatorcontrib><creatorcontrib>Allegrini, Pietro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Continental Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientia pharmaceutica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bray, Luigi</au><au>Monzani, Luca</au><au>Brunoldi, Enrico</au><au>Allegrini, Pietro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product</atitle><jtitle>Scientia pharmaceutica</jtitle><addtitle>Sci Pharm</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>83</volume><issue>2</issue><spage>269</spage><epage>278</epage><pages>269-278</pages><issn>0036-8709</issn><eissn>2218-0532</eissn><abstract>Cilostazol is a selective inhibitor of type 3 phosphodiesterase. 5-(3-Chloropropyl)-1-cyclohexyl-1H-tetrazole, used as an intermediate in the synthesis of cilostazol, has a primary alkyl chloride group, a well-known alerting function for genotoxic activity. Upon request from a regulatory agency, a limit test in accordance with ICH Q2(R1) added with the accuracy of a recovery test of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole in cilostazol was developed and validated. The application of the method highlighted the need to optimize the purification process to ensure levels of this potential genotoxic impurity in the final active pharmaceutical ingredient below the established limit. Also, the analytical method was suitable to determine the amount of the impurity in samples of the commercially available drug product, which showed the levels to be above the established threshold of toxicological concern (TTC).</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>26839820</pmid><doi>10.3797/scipharm.1502-05</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0036-8709
ispartof Scientia pharmaceutica, 2015-01, Vol.83 (2), p.269-278
issn 0036-8709
2218-0532
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4727775
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
title A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A29%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Validated%20HPLC/MS%20Limit%20Test%20Method%20for%20a%20Potential%20Genotoxic%20Impurity%20in%20Cilostazol%20and%20its%20Quantification%20in%20the%20API%20and%20in%20the%20Commercially%20Available%20Drug%20Product&rft.jtitle=Scientia%20pharmaceutica&rft.au=Bray,%20Luigi&rft.date=2015-01-01&rft.volume=83&rft.issue=2&rft.spage=269&rft.epage=278&rft.pages=269-278&rft.issn=0036-8709&rft.eissn=2218-0532&rft_id=info:doi/10.3797/scipharm.1502-05&rft_dat=%3Cproquest_pubme%3E3716164231%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1688472341&rft_id=info:pmid/26839820&rfr_iscdi=true